Bank Norwegian AS
Bank Norwegian AS rated BBB (stable outlook) by Standard & Poor`s, has mandated SpareBank 1 Markets and Swedbank to arrange an investor presentation on 9 March 2021 at 10.00 CET, where one or more senior preferred bond issues in NOK and/or SEK with tenors up to 4 year may follow. Bond issues with call options will be considered.
In conjunction with the potential bond issues, the company will consider buybacks of BANKN22 (ISIN: NO0010848583) maturing 29 September 2021 and BANKN23 (ISIN: NO0010848591) maturing 29 March 2022.
The potential issuance and buyback are part of Bank Norwegian's general funding and will cover MREL requirements. The contemplated issuance is subject to market conditions.
Contact persons:
CFO Klara-Lise Aasen; phone +47 47 63 55 83; kaa@banknorwegian.no
Head of treasury Mats Benserud; phone +47 95 89 15 39; mbe@banknorwegian.no
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
DeFi Technologies Inc.2.6.2025 13:30:00 CEST | Press release
Dr Manfred Knof joins DeFi Technologies as Chairman of Valour and Strategic Advisor
dsm-firmenich2.6.2025 13:12:47 CEST | Press release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Novonesis (Novozymes A/S)2.6.2025 13:05:24 CEST | Press release
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance
Outlook Therapeutics, Inc.2.6.2025 13:00:00 CEST | Press release
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
Denodo Technologies Inc. (“Denodo”)2.6.2025 13:00:00 CEST | Press release
Denodo University Challenge Now Open: Data and AI for Real-World Impact
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom